NCT03695107 is a clinical trial of Nifedipine controlled released tablets in Chronic Kidney Diseases, sponsored by The Third Xiangya Hospital of Central South University.

Who is sponsoring NCT03695107?

NCT03695107 is sponsored by The Third Xiangya Hospital of Central South University.

What drugs are being tested in NCT03695107?

Interventions in NCT03695107: Nifedipine controlled released tablets.

What condition does NCT03695107 study?

NCT03695107 studies Chronic Kidney Diseases.

Is NCT03695107 still recruiting?

NCT03695107 is currently status unknown. Last updated 19 September 2019.

Last reviewed 2019-09-19 · How we verify

NCT03695107

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on the Effect of PTH on CYP3A4 Activity

Status unknown Last updated 19 September 2019

What this trial tests

trial testing Nifedipine controlled released tablets in Chronic Kidney Diseases in 200 participants. Status unknown.

Timeline

2 October 2019

Primary endpoint
10 September 2020

10 September 2020

Quick facts

Lead sponsor	The Third Xiangya Hospital of Central South University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	2 October 2019
Primary completion	10 September 2020
Estimated completion	10 September 2020
Sites	1 location across China

Drugs / interventions tested

Nifedipine controlled released tablets — full drug profile →

Conditions studied

Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →

Sponsor

The Third Xiangya Hospital of Central South University

Who can join

18 and older, any sex, with Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parathyroid hormone (PTH) may play an important role in the down-regulation of CYP3A4 expression induced by Chronic kidney diseases (CKD). In the study of molecular mechanism, the research group found that the expression of CYP3A2 metabolic enzyme in rat liver decreased in the state of CKD.And PTH may down-regulate the expression of CYP3A4 metabolic enzyme by inhibiting the expression of Nuclear factor- Kilobuse (NF-kB) p65 subunit

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease.
Fu C, Pei Q, Liang W, Yang B, et al · · 2022 · cited 1× · PMID 35860523 · DOI 10.2147/dddt.s362607

Verify or expand the search:

Other recruiting trials for Chronic Kidney Diseases

Currently open trials in the same condition.

NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting

Other The Third Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07353307 — A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia Afte · Phase 3 · recruiting
NCT07123207 — Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Dis · NA · recruiting
NCT07034664 — IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study · recruiting
NCT07093294 — Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter · recruiting
NCT07039097 — A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resectio · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03695107 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Third Xiangya Hospital of Central South University
Last refreshed: 19 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03695107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing